Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Artivion (AORT – Research Report) on January 19 and set a price target of $20.00. The company’s shares opened today at $18.48.
Wise covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, Johnson & Johnson, and Baxter International. According to TipRanks, Wise has an average return of 5.1% and a 59.36% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Artivion with a $23.75 average price target, a 28.52% upside from current levels. In a report released on January 19, Lake Street also reiterated a Buy rating on the stock with a $28.00 price target.
See today’s best-performing stocks on TipRanks >>
AORT market cap is currently $748.7M and has a P/E ratio of -30.33.
Based on the recent corporate insider activity of 73 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AORT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Artivion (AORT) Company Description:
CryoLife, Inc. engages in the manufacture, process and distribution of medical devices. It operates through the following segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of BioGlue; JOTEC products, On-X products, CardioGenesis cardiac laser therapy, PerClot and PhotoFix. The Preservation Services segment focuses on external services revenues from the preservation of cardiac and vascular tissues. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.
Read More on AORT:
